Resume

To offer funding for Alzheimer's drug discovery and preclinical development, clinical trials, and biomarker development research

Funding is open to:
• Researchers, clinicians, and postdoctoral fellows
• Working in academia and biotechnology companies
• Based in the U.S. and worldwide

The ADDF currently accepts grant proposals through five RFPs. (For returning grantees, we accept proposals for follow-on funding and renewals.):

Alzheimer's Combination Therapy Opportunities (ACTO) Program

Purpose: Jointly funded by the ADDF, Alzheimer's Association, and the UK's Alzheimer's Society, the ACTO program supports biomarker-based combination trials testing repurposed drug combinations from Phase 1 through Phase 2 proof of concept.
Next Deadline: Letter of Intent: May 20, 2016; Full Application: August 10, 2016

Preclinical Drug Discovery RFP

Purpose: Seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising preclinical drug discovery and biomarker development programs relevant to Alzheimer's disease, related dementias and cognitive aging.
Avg. Duration: 1-2 years
Avg. Award: $150,000-$600,000
Next Deadlines: Letter of Intent: May 13, 2016; Invited Full Proposal: June 3, 2016 (4/year)

Program to Accelerate Clinical Trials (PACT)

Purpose: Designed to increase the number of novel and repurposed treatments tested in humans for Alzheimer's disease, related dementias and cognitive aging. It funds biomarker-based, proof-of-concept pilot clinical trials for Alzheimer's, as well as Phase 1 safety testing and IND-enabling studies to accelerate new drugs into trials.
Avg.Duration: Varies
Avg. Award: Up to $3 million
NextDeadlines: (4/year) Letter of Intent: May 13, 2016; Invited Full Proposal: June 3, 2016

Accelerating Drug Discovery for Frontotemporal Degeneration RFP

Purpose: Accelerates drug discovery programs and biomarker development for frontotemporal degeneration and is funded in partnership with The Association for Frontotemporal Degeneration (AFTD).
Avg.Duration: 1 year
Avg. Award: $100,000-$200,000
Next Deadline: (1/year) September 2016

ADDF/NIH RFP

Purpose: The RFP supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities.
Avg.Duration: 1-2 years
Avg. Award: Varies
Next Deadline: (Rolling): Proposals accepted on a rolling basis

Additional Information:

https://www.alzdiscovery.org/research-and-grants/funding-opportunities

In case of interest, please contact with FSJD Research's Department.